DEA Law Medical Evaluation 
Cannabis Law Report
JANUARY 30, 2019
To expand the number of manufacturers, the Drug Enforcement Administration (DEA) submitted a notice in the Federal Register on August 11, 2016, soliciting applications for licenses to manufacture marijuana for research purposes. I support the expansion of marijuana manufacturers for scientific research consistent with law.
Connor & Connor PLLC
AUGUST 15, 2024
If Congress would like to change the legal status of marijuana, they would do so before or after the DEA makes a final scheduling decision. Additionally, those who are prescribed medical marijuana will need to obtain valid prescriptions, that are different than the state regulatory requirements for medical marijuana.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
AUGUST 31, 2023
This all looks pretty good right now, but the Drug Enforcement Administration (DEA) and ultimately the Attorney General (AG) have final say on whether to schedule or reschedule marijuana following the HHS recommendation. In any case, the DEA Administrator reports to the AG (through the Deputy AG). The AG could then reschedule.
Cannabis Law Report
MARCH 25, 2019
CPA’s” PUBLISHER: CANNABIS LAW REPORT. The Attorney General forwards the request to the Health and Human Services Secretary and requests a scientific and medical evaluation and recommendation, as specified by 23 USC 811(b-c). If you wish to re-publish this story please do so with following accreditation.
Veriheal
NOVEMBER 7, 2024
THC content) under federal law, signaling a major shift in the U.S. The proposal aims to move cannabis products categorized as “marijuana” from Schedule I to Schedule III under the Controlled Substances Act (CSA), which means that cannabis would be officially recognized by the federal government as having legitimate medical use.
Expert insights. Personalized for you.
63 
Let's personalize your content